[1]
|
V. Noronha, N. Q. Shafi, J. A. Obando and S. Kummar, “Primary Non-Hodgkin’s Lymphoma of the Liver,” Critical Reviews in Oncology/Hematology, Vol. 53, 2005, pp. 199-207. doi:10.1016/j.critrevonc.2004.10.010
|
[2]
|
A. Masood, S. Kairouz, K. H. Hudhud, A. Z. Hegazi and A. Banu, “Primary Non-Hodgkin Lymphoma of Liver,” Current Oncology, Vol. 16, No. 4, 2009, pp. 74-79.
doi:10.3747/co.v16i4.443
|
[3]
|
F. S. Haider, R. Smith and S. Khan, “Primary Hepatic Lymphoma Presenting as Fulminant Hepatic Failure with Hyperferritinemia: A Case Report,” Journal of Medical Case Reports, Vol. 2, 2008, p. 279.
doi:10.1186/1752-1947-2-279
|
[4]
|
J. S. Salmon, M. A. Thompson, R. C. Arildsen and J. P. Greer, “Non-Hodgkin’s Lymphoma Involving the Liver: Clinical and Therapeutic Considerations,” Clinical Lymphoma, Myeloma & Leukemia, Vol. 6, No. 4, 2006, pp. 273-280. doi:10.3816/CLM.2006.n.001
|
[5]
|
R. D. Page, J. E. Romaguera, B. Osborne, et al., “Primary Hepatic Lymphoma: Favorable Outcome after Combination Chemotherapy,” Cancer, Vol. 92, No. 8, 2001, pp. 2023-2029. doi:10.1002/1097-0142(20011015)92:8<2023::AID-CNCR1540>3.0.CO;2-B
|
[6]
|
K. Coenegrachts, D. Vanbeckevoort, K. Deraedt and W. Van Steenbergen, “Mri Findings in Primary Non-Hodgkin’s Lymphoma of the Liver,” JBR-BTR, Vol. 88, No. 1, 2005, pp. 17-19.
|
[7]
|
V. Noronha, N. Q. Shafi, J. A. Obando and S. Kummar, “Primary Non-Hodgkin’s Lymphoma of the Liver,” Critical Reviews in Oncology/Hematology, Vol. 53, No. 3, 2005, pp. 199-207. doi:10.1016/j.critrevonc.2004.10.010
|
[8]
|
M. C. Winter and B. W. Hancock, “Ten Years of Rituximab in NHL,” Expert Opinion on Drug Safety, Vol. 8, No. 2, 2009, pp. 223-235. doi:10.1517/14740330902750114
|
[9]
|
R. Marcus and A. Hagenbeek, “The Therapeutic Use of Rituximab in Non-Hodgkin’s Lymphoma,” European Journal of Haematology, Vol. 77, No. 6, 2007, pp. 5-14.
doi:10.1111/j.1600-0609.2006.00789.x
|